Hepatitis Monthly

Published by: Kowsar

Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients

Mihajlo Jakovljevic 1 , * , Zeljko Mijailovic 2 , Biljana Popovska Jovicic 2 , Predrag Canovic 2 , Olgica Gajovic 2 , Mirjana Jovanovic 3 , Dejan Petrovic 4 , Olivera Milovanovic 5 and Natasa Djordjevic 1
Authors Information
1 Pharmacology and Toxicology Department, The Faculty of Medical Sciences Kragujevac, University of Kragujevac, Kragujevac, Serbia
2 Infectious Diseases Clinic, University Clinical Center Kragujevac, Kragujevac, Serbia
3 Regional Addiction Disorders Center, Psychiatry Clinic, University Clinical Center Kragujevac, Kragujevac, Serbia
4 Urology and Nephrology Clinic, University Clinical Center Kragujevac, Kragujevac, Serbia
5 Department of Pharmacy The Faculty of Medical Sciences University of Kragujevac, Kragujevac, Serbia
Article information
  • Hepatitis Monthly: June 01, 2013, 13 (6); e6750
  • Published Online: June 19, 2013
  • Article Type: Research Article
  • Received: June 11, 2012
  • Revised: January 31, 2013
  • Accepted: April 15, 2013
  • DOI: 10.5812/hepatmon.6750

To Cite: Jakovljevic M, Mijailovic Z, Popovska Jovicic B, Canovic P, Gajovic O, et al. Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients, Hepat Mon. 2013 ; 13(6):e6750. doi: 10.5812/hepatmon.6750.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4): 1147-71[PubMed]
  • 2. Pecic V, Stankovic-Djordjevic D, Nestorovic M, Radojkovic M, Marjanovic H, Ilic B, et al. Hepatitis C virus-related hepatocellular carcinoma and liver cirrhosis. J Buon. 2011; 16(2): 277-81[PubMed]
  • 3. Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol. 2007; 13(17): 2461-6[PubMed]
  • 4. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature. 2005; 436(7053): 953-60[PubMed]
  • 5. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol. 2007; 13(17): 2416-26[PubMed]
  • 6. Lee CM, Hung CH, Lu SN, Changchien CS. Hepatitis C virus genotypes: clinical relevance and therapeutic implications. Chang Gung Med J. 2008; 31(1): 16-25[PubMed]
  • 7. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000; 13(2): 223-35[PubMed]
  • 8. Kuljic-Kapulica N, Jovanovic D, Savic D, Ristanovic E, Nozic D, Rajic R. [Therapy of chronic hepatitis C--virologic response monitoring]. Vojnosanit Pregl. 2010; 67(11): 923-7[PubMed]
  • 9. Briggs A, Shiell A. Interferon-alpha in hepatitis C. Dosage, costs and benefits. Pharmacoeconomics. 1996; 10(3): 205-9[PubMed]
  • 10. Garcia de Ancos JL, Roberts JA, Dusheiko GM. An economic evaluation of the costs of alpha-interferon treatment of chronic active hepatitis due to hepatitis B or C virus. J Hepatol. 1990; 11 Suppl 1-8[PubMed]
  • 11. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011; 15(17)-210[PubMed]
  • 12. Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P, et al. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci. 2011; 56(10): 3024-31[PubMed]
  • 13. Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg. 1998; 61(2): 238-42[PubMed]
  • 14. Nikolic P, Jemuovic L, Delic D, Korac M, Boricic I. Treatment of chronic hepatitis C with interferon alpha – our results. Acta Infectologica Yugoslavica. 2000; 5: 1-9
  • 15. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005; 42(4): 962-73[PubMed]
  • 16. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007; 39(2): 175-91[PubMed]
  • 17. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006; 130(4): 1086-97[PubMed]
  • 18. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up. J Viral Hepat. 2012; 19(2)-104[PubMed]
  • 19. Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature. A review. Int J Technol Assess Health Care. 1998; 14(4): 799-808[PubMed]
  • 20. Matsuura K, Tanaka Y, Hasegawa I, Ohno T, Tokuda H, Kurbanov F, et al. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J Clin Microbiol. 2009; 47(2): 385-9[PubMed]
  • 21. Health statistical yearbook of Republic of Serbia 2010. 2010;
  • 22. Annemans L. Health economics for non-economists: an introduction to the concepts, methods and pitfalls of health economic evaluations. 2008;
  • 23. Gajic-Stevanovic M, Vuksa A, Zivkovic S, Teodorovic N. Cost of primary health care in the Republic of Serbia for the period 2006-2008. Serbian Dental J. 2010; 57: 86-97
  • 24. Gerkens S, Nechelput M, Annemans L, Peraux B, Mouchart M, Beguin C, et al. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat. 2007; 14(8): 523-36[PubMed]
  • 25. O'Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics. 2000; 17(4): 339-49[PubMed]
  • 26. Carlsson T, Quist A, Weiland O. Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. J Med Virol. 2008; 80(5): 803-7[PubMed]
  • 27. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, et al. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012;
  • 28. Romeo JM, Ulrich PP, Busch MP, Vyas GN. Analysis of hepatitis C virus RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors. Hepatology. 1993; 17(2): 188-95[PubMed]
  • 29. Singal AK, Anand BS. Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2010; 44(8): 583-7[PubMed]
  • 30. Glied S. Mandates and the affordability of health care. Inquiry. 2009; 46(2): 203-14[PubMed]
  • 31. Noble SM, Hollingworth W, Tilling K. Missing data in trial-based cost-effectiveness analysis: the current state of play. Health Econ. 2012; 21(2): 187-200[PubMed]
  • 32. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010; 52(2): 436-42[PubMed]
  • 33. Shah NM, Brieger WR, Peters DH. Can interventions improve health services from informal private providers in low and middle-income countries?: a comprehensive review of the literature. Health Policy Plan. 2011; 26(4): 275-87[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments